Last Update:
January 26, 2015
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader .
Perinatal data are integrated with Perinatal Conference Data in the
Perinatal Data Page. Pediatric data are integrated with
Pediatric Conference Data in the Pediatric Data Page
CC
Lawrence, A Thomas, W Yuan, et al
Abstract
Comparison of the gastrointestinal tolerability and patient
preference for treatment with the
Roche Nelfinavir 625 mg and 250 mg (Viracept®) tablet formulations
M Johnson, L Nieto-Cisneros, A Horban, et
al
Abstract
Impact
of Nelfinavir-resistance mutations on the Human Immunodeficiency Virus type 1
with
subtype B and C proteases
LMF Gonzalez-Olivieri, R Brindeiro, M
Soares, et al
Abstract
The introduction of nelfinavir-containing antiretroviral therapy does not
increase the estimated
cardiovascular risk at 6 months in HIV-infected adults
E Martinez, P Viciana, F
Pulido, et al
Abstract
Effects
of highly active antiretroviral therapy with nelfinavir on immune activation and
reconstitution markers in HIV-1-infected patients
IV Korzh, IF Fedotova, VD
Nemtsova, et al
Abstract
An
analysis of nelfinavir adherence, resistance, and HIV viral load
AK Wutoh, M Daftary, Z Xue, EA Nwankwo
Abstract
Influence of Single-nucleotide polymorphisms of the multidrug resistance-1 gene
on export of
nelfinavir from lymphoblastoid cell lines and clinical response to
antiretroviral therapy in
Japanese patients infected with human immunodeficiency virus type 1
D Zhu, H Nakamura, M Goto, et
al
Abstract
-
POSTER
Evaluation of HCV RNA and Liver Injury in HCV/HIV Co-infected
Patients Initiating Lopinavir/r or
Nelfinavir-based Therapy
KE Sherman, NJ Shire, P Cernohous, et al
PDF
Poster
Abstract
-
POSTER
Sex and Weight as Covariates in the Pharmacokinetics of Efavirenz,
Indinavir, and Nelfinavir
J Hitti, S Rosenkranz, S Cohn. et al
PDF
Poster
Abstract
|
|
-
POSTER
Variability in Alpha-1 Acid Glycoprotein and its Impact on Nelfinavir Free
Fraction in HIV-
Infected Subjects
S Au, A Gates, T Blaschke, et al.
PDF Poster -
Clinical
pharmacokinetics of nelfinavir and its metabolite M8 in HIV/HCV co-infected
patients with
and without
cirrhosis.
MB Regazzi, P.Villani, P. Zucchi, et al
Poster-
Efavirenz and Nevirapine concentration-effect relationships in HIV infected
patients pharmacologically
followed
by routine therapeutic drug monitoring (TDM)
Garraffo R,
Lavrut T, Pierre B, et al.
Abstract
-
POSTER
Improved Gastrointestinal (GI) Tolerability of Roche Nelfinavir 625 mg
Film-Coated Tablets in
Comparison with Nelfinavir 250 mg Film-Coated Tablets (Viracept)
B Kaeser, D-J Akintola, A Saifulanwar, et al
PDF Poster
|
, et al,
Abstract
THE
EFFECT OF ILLICIT DRUG USE, METHADONE MAINTENANCE PROGRAM AND PAST
ILLICIT DRUG USE ON TREATMENT OUTCOME IN A LARGE COHORT OF PATIENTS
TREATED
WITH NELFINAVIR
H Knobel, J Collazos, JL Casado,
et al
Abstract
POPULATION PHARMACOKINETICS OF INDINAVIR AND NELFINAVIR/M8 IN HIV-PATIENTS
TREATED WITH A STABLE ANTIRETROVIRAL THERAPY
K. Brendel, X. Panhard,
M. Legrand, et al
Abstract
POPULATION PHARMACOKINETICS OF INDINAVIR AND NELFINAVIR/M8 IN HIV-PATIENTS
TREATED WITH A STABLE ANTIRETROVIRAL THERAPY
F Mentré, K Brendel,
X. Panhard, et al
Abstract
POPULATION PHARMACOKINETICS OF NELFINAVIR (NFV) ADMINISTERED BID OR TID AND
PHARMACOKINETIC PREDICTORS OF HIV SUPPRESSION
PH. Hsyu, EV Capprelli, J Lane,
et al
Abstract
ROCHE
VIRACEPT (NELFINAVIR) 625 MG FILM-COATED TABLETS: INVESTIGATION OF
SAFETY AND GASTROINTESTINAL TOLERABILITY OF THIS NEW FORMULATION IN
COMPARISON WITH 250 MG FILM-COATED TABLETS (VIRACEPTâ) IN HIV PATIENTS
M. Johnson, L. Nieto-Cisneros, A. Horban,
et al
Abstract
IMPACT
OF NELFINAVIR (NFV) AND ITS ACTIVE METABOLITE M8 TROUGH LEVELS (TL) ON
VIROLOGIC RESPONSE FROM PRIMARY HIV-1 VERTICALLY INFECTED CHILDREN TREATED
WITH STAVUDINE (D4T), DIDANOSINE (DDI) AND NFV IN THE PENTA 7 STUDY
A. Compagnucci, Y. Saïdi, A. Faye,
et al
Abstract
LIPID
PROFILE ALTERATIONS INDUCED BY THREE DIFFERENT PI-CONTAINING REGIMENS
(NELFINAVIR, LOPINAVIR/RITONAVIR AND INDINAVIR/RITONAVIR) IN A COHORT OF HIV-
INFECTED PATIENTS
V. Joly, J. Gerbe, F. Driss,
et al
Abstract
IMPACT
OF NELFINAVIR (NFV) AND ITS ACTIVE METABOLITE M8 TROUGH LEVELS (TL) ON
VIROLOGIC RESPONSE FROM PRIMARY HIV-1 VERTICALLY INFECTED CHILDREN TREATED
WITH
STAVUDINE (D4T), DIDANOSINE (DDI) AND NFV IN THE PENTA 7 STUDY
Compagnucci, Y. Saïdi, A. Faye,
et al
Abstract
STEP-WISE INTERVENTION FOR THE MANAGEMENT OF NELFINAVIR (NFV)-ASSOCIATED
DIARRHEA
A. Rachlis, M.J. Gill, J.G. Baril,
et al
Abstract
TRANSVERSAL STUDY TO CORRELATE PLASMA NELFINAVIR CONCENTRATION,
ANTIRETROVIRAL THERAPY COMPLIANCE, AND GENOTYPE RESISTANCE/DIFFERENCES
IN HIV
POSITIVE PATIENTS IN STABLE TREATMENT
A. Cassinello, S. García, P. Guerra,
et al
Abstract
|
11th
CROI
4th
International Workshop on Clinical Pharm of HIV
2nd
IAS Conference
